No credible evidence suggests that melatonin causes cancer. The research consistently points in the opposite direction: melatonin appears to have anti-cancer properties across a range of tumor types, both in laboratory studies and in early clinical work. The real concern isn’t that taking melatonin promotes cancer but that losing melatonin, through night-shift work, chronic light exposure after dark, or aging, may leave your body more vulnerable to it. The story is more layered than a simple “safe or dangerous” verdict, though, and the details matter if you’re someone who takes melatonin regularly or is considering it during cancer treatment.
Why the Question Comes Up in the First Place
Melatonin is a hormone your pineal gland produces mainly at night in response to darkness. Its secretion follows a circadian rhythm driven by the brain’s internal clock and synchronized to the light-dark cycle.1PubMed. Melatonin: Physiological effects in humans Three features define the melatonin system: it is sensitive to light, it peaks at night, and it declines with age.2PubMed. Melatonin and its physiological and therapeutic properties That age-related drop, combined with the explosion in artificial light and screen use after dark, means most modern adults produce less melatonin than their bodies were designed for.
The cancer question usually arises from one of two directions. First, people hear that melatonin is a “hormone” and worry that supplementing it could fuel hormone-sensitive cancers the way estrogen can fuel certain breast tumors. Second, headlines about night-shift work and cancer risk sometimes mention melatonin suppression, leaving readers unsure whether melatonin is part of the problem or the solution. The short version: it’s the solution. The International Agency for Research on Cancer has classified night-shift work as a probable human carcinogen, and one of the key mechanisms thought to explain that link is the suppression of melatonin caused by exposure to light at night.3PubMed Central. Night shift work and breast cancer: from etiopathology to precision risk analysis In other words, having less melatonin is associated with higher cancer risk, not the other way around.
How Melatonin Works Against Cancer Cells
The anti-cancer properties of melatonin have been studied for decades, and the mechanisms are surprisingly varied. In breast cancer specifically, melatonin interferes with estrogen signaling. Lab experiments show it reduces estrogen receptor activation and blocks estrogen-driven gene expression in breast cancer cells.4PubMed. Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells It can also dampen the activity of estrogen receptors on genes that help breast cancer stem cells renew themselves, reducing both the receptor’s binding and the expression of stemness-related genes.5PubMed Central. Melatonin decreases estrogen receptor binding to estrogen response elements sites on the OCT4 gene in human breast cancer stem cells Beyond estrogen pathways, melatonin independently lowers free-radical formation, which helps prevent the DNA damage that can kick off the mutation-to-cancer chain.6PubMed Central. Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives
One of the more striking findings involves how melatonin treats normal and cancer cells differently. At low concentrations, it activates programmed cell death pathways inside cancer cells while simultaneously protecting healthy cells from the same fate.7PubMed Central. Melatonin drives apoptosis in head and neck cancer by increasing mitochondrial ROS generated via reverse electron transport Researchers have described this as a “smart killer” effect: melatonin pushes cancer cells toward death while shielding normal tissue from damage. Even in tumor types that don’t respond well to melatonin alone, it can amplify the cell-killing effects of conventional chemotherapy drugs.
The Mitochondrial Angle
Cancer cells famously rewire their energy metabolism, relying heavily on a less efficient glucose-burning process even when oxygen is available. Melatonin appears to counteract this metabolic shift. Research suggests it can nudge cancer cells back toward normal mitochondrial function, which in turn makes those cells more susceptible to the body’s built-in self-destruct signals.8PubMed Central. Melatonin, mitochondria, and the cancer cell This dual action, restoring healthy mitochondrial behavior while triggering cancer cell death, is part of why melatonin keeps showing up as a candidate for combination cancer therapy rather than as a risk factor.
Immune System Effects
Your immune system’s ability to detect and destroy abnormal cells is one of your primary natural defenses against cancer. Melatonin has been shown to boost the activity of natural killer cells and cytotoxic T cells, both of which hunt and kill cancer cells directly. At the same time, it appears to weaken the activity of regulatory T cells and cancer-associated fibroblasts, which are cell types that tumors co-opt to evade immune surveillance.9PubMed. Boosting immune system against cancer by melatonin: A mechanistic viewpoint
Animal studies have pushed this further. In mice with lung tumors, melatonin enhanced the infiltration and activation of natural killer cells within tumor tissue when combined with a tumor-ablation technique. The natural killer cells showed increased markers of activation and higher production of tumor-fighting signaling molecules. In lab cultures, melatonin directly improved the ability of natural killer cells to destroy cancer cells in a dose-dependent manner.10Signal Transduction and Targeted Therapy. Melatonin enhances radiofrequency-induced NK antitumor immunity, causing cancer metabolism reprogramming and inhibition of multiple pulmonary tumor development These are animal and in-vitro results, not human clinical outcomes, but the consistency of the immune-boosting signal across studies is hard to ignore.
What Happens When You Lose Melatonin
The flip side of melatonin’s protective effects is what happens when your body can’t make enough. Shift workers who regularly work nights are the most studied population here. Their exposure to artificial light during normal darkness hours suppresses melatonin production, and they carry a higher risk of several cancer types, breast cancer in particular.11PubMed Central. Measuring Light at Night and Melatonin Levels in Shift Workers: A Review of the Literature Multiple mechanisms likely contribute to this risk, including melatonin suppression, oxidative stress, immune disruption, chronic inflammation, altered clock-gene expression, and changes to estrogen signaling.3PubMed Central. Night shift work and breast cancer: from etiopathology to precision risk analysis
Researchers still debate whether the melatonin drop alone drives the added cancer risk or whether broader circadian disruption is the culprit. The honest answer is probably both, and untangling their individual contributions in humans is genuinely difficult. But either way, the evidence reinforces the same conclusion: less melatonin correlates with more cancer risk, not less.
Specific Cancer Types Beyond Breast
Most of the early melatonin-cancer research focused on breast tumors, but the picture has broadened considerably. In prostate cancer, melatonin limits cell growth partly by causing the androgen receptor to be pushed out of the cell nucleus, blunting the hormone signals that prostate cancer depends on.12PubMed Central. Melatonin and Prostate Cancer: Anti-tumor Roles and Therapeutic Application This nuclear exclusion of the androgen receptor has been replicated across multiple studies using prostate cancer cell lines.13PubMed. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism
In gastrointestinal cancers, melatonin’s presence in the gut at high concentrations gives it a local protective role. It strengthens the intestinal barrier, tamps down inflammation, and reduces oxidative stress, all of which are relevant to colorectal cancer development.14PubMed Central. Mechanism of Action of Melatonin as a Potential Adjuvant Therapy in Inflammatory Bowel Disease and Colorectal Cancer Melatonin also inhibits the production of VEGF, a protein tumors use to build their own blood supply, in pancreatic cancer cells and neuroblastoma cells.15PubMed Central. Melatonin inhibits the expression of vascular endothelial growth factor in pancreatic cancer cells16PubMed. Melatonin inhibits angiogenesis in SH-SY5Y human neuroblastoma cells by downregulation of VEGF Cutting off a tumor’s blood supply is one of the major strategies in modern cancer treatment, so the fact that melatonin does this in the lab is particularly interesting.
Brain cancers tell a nuanced story about melatonin receptors. In gliomas, the expression ratio between melatonin’s two main receptors, MT1 and MT2, correlates with prognosis. Gliomas show decreased MT1 and increased MT2 compared to normal brain tissue, and a higher MT1-to-MT2 ratio is associated with better outcomes.17PubMed. MT1 and MT2 melatonin receptors play opposite roles in brain cancer progression In non-small-cell lung cancer, higher MT2 expression independently predicted longer survival, and both MT1 and MT2 expression tended to decline as tumors grew larger and more advanced.18PubMed Central. Prognostic Impact of Melatonin Receptors MT1 and MT2 in Non-Small Cell Lung Cancer (NSCLC)
Melatonin and Cancer Stem Cells
Cancer stem cells are a particularly tough subset of tumor cells thought to drive relapse and resistance to treatment. Several lab studies suggest melatonin can target these cells. In ovarian cancer stem cells, melatonin reduced the expression of key stemness markers and a proliferation marker, effectively dialing down the cells’ ability to maintain their stem-like state.19Scientific Reports. The potential therapeutic effect of melatonin on human ovarian cancer by inhibition of invasion and migration of cancer stem cells In brain tumor stem cells, melatonin triggered a chemical modification of a drug-resistance gene’s promoter region that reduced the gene’s expression, making the cells more sensitive to chemotherapy drugs.20British Journal of Cancer. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells This is still early-stage science, but it hints at why melatonin keeps appearing in discussions about combination therapy: it may help address the cells that conventional treatment misses.
Clinical Use Alongside Cancer Treatment
Moving from lab bench to bedside, a systematic review and meta-analysis of randomized trials found that melatonin as an add-on to chemotherapy, radiotherapy, or supportive care improved survival and reduced chemotherapy side effects in cancer patients.21PubMed. Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials This doesn’t mean melatonin is a proven cancer treatment on its own, and much of the clinical trial evidence comes from studies that were relatively small or varied in quality. But the overall direction, reduced side effects and possibly longer survival, is consistent enough that researchers continue to explore it seriously.
The interest in melatonin as a complement to standard oncology isn’t about replacing surgery, chemotherapy, or immunotherapy. It’s about whether a well-tolerated molecule can make existing treatments work better while protecting healthy tissue from collateral damage. That dual-selectivity characteristic, hurting cancer cells while shielding normal ones, makes it an appealing candidate.
Safety Profile and Dose Concerns
For typical sleep-aid doses of a few milligrams, melatonin is widely considered safe for short- and medium-term use. A systematic review and meta-analysis looking at higher doses found no detectable increase in serious adverse events, though it did find a modestly higher rate of non-serious effects like drowsiness, headache, and dizziness.22PubMed. Safety of higher doses of melatonin in adults: A systematic review and meta-analysis One small study in patients undergoing major liver surgery found a single high preoperative dose was well tolerated with no serious events.23PubMed. The use of high-dose melatonin in liver resection is safe: first clinical experience
That said, one important caution emerged from a recent clinical trial testing very high doses of melatonin alongside another medication in patients with progressive multiple sclerosis. Some participants developed liver enzyme elevations, raising concerns about liver toxicity when high-dose melatonin is combined with other drugs that share the same liver processing pathways.24PubMed Central. Hepatic Safety of Adjunctive High-Dose Melatonin in Participants Receiving Ocrelizumab for Primary Progressive Multiple Progressive Multiple Sclerosis: Liver Toxicity Findings from a Phase I/II Randomised Clinical Trial (MELATOMS-1) The issue wasn’t melatonin alone but rather a drug-drug interaction that overwhelmed the liver’s capacity to metabolize everything at once. If you take multiple medications, especially ones processed through the liver, talking to your doctor before adding high-dose melatonin is genuinely worth doing.
The Supplement Quality Problem
One underappreciated risk has nothing to do with melatonin itself and everything to do with how supplements are manufactured. Because melatonin is sold as a dietary supplement in countries like the United States, it isn’t subject to the same quality controls as prescription drugs. Testing of commercial melatonin products has found serotonin, a related compound that is a controlled substance in some therapeutic contexts, present in eight of the products tested, at levels ranging from 1 to 75 micrograms.25PubMed Central. Melatonin Natural Health Products and Supplements: Presence of Serotonin and Significant Variability of Melatonin Content Separate analysis has identified tryptophan-related contaminants in melatonin supplements, prompting calls for tighter impurity controls.26Journal of Food Composition and Analysis. Quality control and determination of melatonin in food supplements
This means that some of the adverse reactions people attribute to melatonin may actually be caused by contaminants or wildly inconsistent dosing rather than the hormone itself. If you’re going to take melatonin, choosing a product from a manufacturer that does third-party testing and holds a USP or NSF certification is a practical way to reduce that variable.
Melatonin in Children
Parents often worry about giving melatonin to children, and the cancer question is part of broader safety concerns that include effects on puberty and development. One major worry, that long-term melatonin use could delay puberty, has some theoretical basis from animal studies but little clinical support. A review found no clinical studies that had experimentally tested whether melatonin affects pubertal timing in children.27PubMed Central. Could long-term administration of melatonin to prepubertal children affect timing of puberty? A clinician’s perspective A two-year study of prolonged-release melatonin in children with autism found that changes in weight, height, and pubertal development all stayed within normal ranges, with no evidence of delay.28PubMed Central. Sleep, Growth, and Puberty After 2 Years of Prolonged-Release Melatonin in Children With Autism Spectrum Disorder Another study of children who had taken melatonin long-term for chronic sleep-onset insomnia found pubertal staging scores that were statistically indistinguishable from those in the general population.29PubMed Central. Evaluation of sleep, puberty and mental health in children with long-term melatonin treatment for chronic idiopathic childhood sleep onset insomnia None of these studies raised cancer signals, though they weren’t designed to look for them specifically.
Melatonin and Gut Health
An emerging area of research connects melatonin to the gut microbiome in ways that may be relevant to cancer prevention. Your gut produces its own melatonin independently of the pineal gland, and the concentrations there are considerably higher than in the blood. In animal models, melatonin increased the diversity of gut bacteria and boosted populations of bacteria that produce short-chain fatty acids, particularly butyrate. Butyrate then suppressed a key inflammatory signaling pathway in immune cells lining the intestine, reducing the kind of chronic low-grade inflammation that, over time, contributes to colorectal cancer risk.30PubMed. Microbial Butyrate Modified by Melatonin Alleviates Colon Inflammation by Inhibiting GPR109A/Caspase-1-Dependent Macrophage M1 Polarization This is still early research in mice, and translating gut microbiome findings to humans is notoriously tricky. But it adds another thread to the story of how melatonin interacts with cancer-related biology far beyond the pineal gland.
What the Epigenetic Research Suggests
Some of the newest findings involve melatonin’s ability to influence how genes are switched on or off without changing the underlying DNA sequence. This kind of regulation matters for cancer because tumors frequently hijack these switches to silence tumor-suppressor genes or activate growth-promoting ones. Research on oral cancer and other tumor types indicates melatonin can reverse some of these abnormal gene-regulation patterns, potentially restoring anti-cancer gene activity that the tumor had shut down.31PubMed Central. Potential of melatonin to reverse epigenetic aberrations in oral cancer: new findings The brain tumor stem cell study mentioned earlier offers a concrete example: melatonin triggered a chemical modification at a specific gene promoter that made drug-resistant stem cells responsive to chemotherapy again.20British Journal of Cancer. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells If these effects hold up in clinical settings, melatonin could become useful not as a standalone cancer drug but as something that makes existing treatments more effective by resetting the molecular switches tumors have manipulated.